Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.053
Buy
RSI(14)
58.556
Neutral
STOCH(KDJ)(9,3,3)
80.085
Neutral
ATR(14)
0.073
High Vlolatility
CCI(14)
101.660
Buy
Williams %R
19.367
Overbought
TRIX(12,20)
0.479
Sell
StochRSI(14)
20.418
Sell
Search
Rani Therapeutics Holdings Inc
RANIAdd to Watchlist
1.080USD
-0.030-2.70%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
133.69MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Rani Therapeutics Holdings Inc
Currency: USD Updated: 2026-05-15Key Insights
Rani Therapeutics Holdings Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 124 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to trend down.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Rani Therapeutics Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Rani Therapeutics Holdings Inc Highlights
StrengthsRisks
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. The Company has developed the RaniPill capsule, which is a proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. The RaniPill capsule is designed to deliver a variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. It has two configurations of the platform: the RaniPill GO and the RaniPill HC. The RaniPill GO is designed to deliver up to a 3 mg dose of drug in microtablet form with high bioavailability. It is also developing a high-capacity version of the RaniPill capsule known as the RaniPill HC. Its product candidate pipeline includes obesity programs (RT-114 and RT-116), immunology programs (RT-105 and RT-111) and endocrinology programs (RT-102 and RT-110).
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.63M.
Undervalued
The company’s latest PE is -3.99, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 52.09M shares, increasing 26.74% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 5.14K shares of this stock.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
7.500
Target Price
+575.68%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Rani Therapeutics Holdings Inc is 5.68, ranking 328 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 1.71M, representing a year-over-year increase of 893.02%, while its net profit experienced a year-over-year increase of 3.18%.
Score
Financials
5.38
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.23
Operational Efficiency
2.57
Growth Potential
6.06
Shareholder Returns
7.13
Rani Therapeutics Holdings Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Rani Therapeutics Holdings Inc is 8.76, ranking 22 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.99, which is -88.68% below the recent high of -0.45 and -52.69% above the recent low of -6.10.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 124/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Rani Therapeutics Holdings Inc is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 9.50, with a high of 11.00 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
7.500
Target Price
+575.68%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Rani Therapeutics Holdings Inc
RANI
4
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Rani Therapeutics Holdings Inc is 6.32, ranking 260 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.20 and the support level at 0.89, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.082
Sell
MA10
1.008
Buy
MA20
0.963
Buy
MA50
1.004
Buy
MA100
1.172
Sell
MA200
1.131
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Rani Therapeutics Holdings Inc is 1.11, ranking 335 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.79. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.80
VaR
+8.96%
240-Day Maximum Drawdown
+74.22%
240-Day Volatility
+176.90%
Return
Best Daily Return
60 days
+14.65%
120 days
+17.39%
5 years
+248.27%
Worst Daily Return
60 days
-24.94%
120 days
-24.94%
5 years
-38.92%
Sharpe Ratio
60 days
-0.37
120 days
-0.79
5 years
+0.22
Risk Assessment
Maximum Drawdown
240 days
+74.22%
3 years
+94.78%
5 years
+98.83%
Return-to-Drawdown Ratio
240 days
+1.27
3 years
-0.26
5 years
-0.18
Skewness
240 days
+11.75
3 years
+14.31
5 years
+13.74
Volatility
Realised Volatility
240 days
+176.90%
5 years
+132.59%
Standardised True Range
240 days
+11.14%
5 years
+61.09%
Downside Risk-Adjusted Return
120 days
-113.11%
240 days
-113.11%
Maximum Daily Upside Volatility
60 days
+63.88%
Maximum Daily Downside Volatility
60 days
+66.26%
Liquidity
Average Turnover Rate
60 days
+2.74%
120 days
+3.60%
5 years
--
Turnover Deviation
20 days
-77.30%
60 days
-70.00%
120 days
-60.50%
Peer Comparison
Biotechnology & Medical Research
Rani Therapeutics Holdings Inc
RANI
6.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
